Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is well-positioned for success due to their strong pipeline of rare disease therapies, including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). The recent approval of sparsentan for FSGS, the first FDA-approved medication for this rare kidney disorder, greatly expands Travere's addressable market and should drive significant revenue growth in the coming years. With continued positive results from their ongoing clinical trials and a strong management team, we expect Travere's stock to continue performing well in the long term.

Bears say

Travere Therapeutics is expecting a rapid adoption of sparsentan, which could potentially increase the total number of addressable patients for Filspari to over 100,000 and generate peak US sales of more than $3 billion. However, there are risks including a potential need for additional capital and any delays or setbacks in the commercialization of their products, which could negatively impact the company's valuation. Additionally, while the company currently has a positive outlook, only time will tell if they are able to meet their projected timelines and sales potential.

Travere Therapeutics (TVTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 11 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of May 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.